CHAF1A and neoplasm: Our strategy is confirmed as valid for the identification of novel tumor-suppressive miRNA such as miR-323a-5p and miR-342-5p in NB models, including but not limited to the ones that are resistant to conventional therapies and reveals new vulnerabilities of high-risk NB through the combined inhibition of targets such as CCND1, CHAF1A, INCENP and BCL-XL.